Article · 26 Feb 2026
Review articlePublished 15 Jul 2016
Viral clearance for biopharmaceutical downstream processes
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Viral clearance studies are mandated prior to entering clinical trials and for commercial launch of biopharmaceuticals. These studies are a key component of risk mitigation to reduce the potential for iatrogenic transmission of pathogenic viruses. This paper reviews regulatory guidance and practical strategies for designing viral clearance studies. Essential elements of a developmental phase-appropriate viral clearance package are detailed. These include scale-down model qualification, virus spike experiments and validation (clearance evaluation) of manufacturing process steps. Heuristics and learnings from available data are shared. Developments in this area including generic validation strategies, multiviral spiking strategies and use of newer model viruses for nonconventional substrates are also described. This review provides a framework for a comprehensive viral validation package for regulatory submissions.
Keywords
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Pharmaceutical Bioprocessing.
Article · 29 Nov 2025
Adaptive Bioprocess Control: Enabling Intelligent and Robust Biomanufacturing
Article · 29 Nov 2025
Advanced Foam Control Strategies in Bioprocessing
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPharmaceutical Bioprocessing
- SubjectPharmaceutical Sciences
- SubjectBiochemistry & Biotechnology
- BylineArticles whose byline prints “Abhinav A Shukla”
- BylineArticles whose byline prints “Hazel Aranha”
